LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2. - Dataset (ID:20249)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
MCF7 | Palbociclib | 0.04 | uM | LJP6 | 72 | hr | 1389 | 4400 | 5445 | 0.8075 | 0.7926 |
MCF7 | Erlotinib | 0.04 | uM | LJP5 | 72 | hr | 1389 | 5185 | 5905 | 0.8788 | 0.8801 |
MCF7 | BX-912 | 0.04 | uM | LJP5 | 72 | hr | 1389 | 4745 | 5905 | 0.8033 | 0.8007 |
MCF7 | CGP60474 | 0.04 | uM | LJP5 | 72 | hr | 1389 | 5969 | 5905 | 1.0110 | 1.0106 |
SK-BR-3 | PIK-93 | 0.04 | uM | LJP5 | 72 | hr | 2543 | 6046 | 5752 | 1.0512 | 1.0866 |
MCF7 | CGP60474 | 0.04 | uM | LJP6 | 72 | hr | 1389 | 727 | 5445 | 0.1339 | -0.2802 |
MCF7 | Dovitinib | 0.04 | uM | LJP5 | 72 | hr | 1389 | 5070 | 5905 | 0.8580 | 0.8580 |
SK-BR-3 | Mitoxantrone | 0.04 | uM | LJP5 | 72 | hr | 2543 | 2003 | 5752 | 0.3482 | -0.1839 |
MCF7 | Selumetinib | 0.04 | uM | LJP6 | 72 | hr | 1389 | 4868 | 5445 | 0.8954 | 0.8915 |
SK-BR-3 | AT-7519 | 0.04 | uM | LJP6 | 72 | hr | 2543 | 5140 | 5418 | 0.9491 | 0.9072 |
SK-BR-3 | Radicicol | 0.04 | uM | LJP6 | 72 | hr | 2543 | 3341 | 5418 | 0.6157 | 0.2801 |
SK-BR-3 | AZD7762 | 0.04 | uM | LJP6 | 72 | hr | 2543 | 2030 | 5418 | 0.3747 | -0.1872 |
SK-BR-3 | Withaferin A | 0.04 | uM | LJP6 | 72 | hr | 2543 | 5809 | 5418 | 1.0736 | 1.1383 |
SK-BR-3 | Alvocidib | 0.04 | uM | LJP6 | 72 | hr | 2543 | 2952 | 5418 | 0.5448 | 0.1453 |
MCF7 | MK2206 | 0.04 | uM | LJP6 | 72 | hr | 1389 | 4071 | 5445 | 0.7484 | 0.7262 |
SK-BR-3 | Sorafenib | 0.04 | uM | LJP6 | 72 | hr | 2543 | 5284 | 5418 | 0.9764 | 0.9589 |
MCF7 | Afatinib | 0.04 | uM | LJP6 | 72 | hr | 1389 | 4541 | 5445 | 0.8383 | 0.8287 |
MCF7 | HG-5-88-01 | 0.04 | uM | LJP6 | 72 | hr | 1389 | 3675 | 5445 | 0.6770 | 0.6408 |
SK-BR-3 | CP466722 | 0.04 | uM | LJP5 | 72 | hr | 2543 | 6180 | 5752 | 1.0744 | 1.1255 |
MCF7 | GSK 690693 | 0.04 | uM | LJP5 | 72 | hr | 1389 | 4087 | 5905 | 0.6919 | 0.6763 |
MCF7 | AZD-6482 | 0.04 | uM | LJP5 | 72 | hr | 1389 | 6084 | 5905 | 1.0297 | 1.0278 |
MCF7 | CP466722 | 0.04 | uM | LJP5 | 72 | hr | 1389 | 6297 | 5905 | 1.0662 | 1.0623 |
MCF7 | Gefitinib | 0.04 | uM | LJP6 | 72 | hr | 1389 | 5921 | 5445 | 1.0878 | 1.0876 |
MDA-MB-231 | CGP60474 | 0.04 | uM | LJP5 | 72 | hr | 1311 | 3853 | 5079 | 0.7584 | 0.7356 |
MDA-MB-231 | NVP-TAE684 | 0.04 | uM | LJP6 | 72 | hr | 1311 | 4655 | 4935 | 0.9432 | 0.9396 |